Floatz Rating
D31/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
22High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06498973CT.gov Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant | — | Recruiting | — | — | — |
NCT05720988CT.gov Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT05716009CT.gov Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML | — | Active Not Recruiting | — | — | — |
NCT02270463CT.gov SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tagraxofusp-Erzs (this asset) | City of Hope Medical Center | P1/2 | D · 31 |
| Gemtuzumab | M.D. Anderson Cancer Center | P4 | BBB |
| Posaconazole | AstraZeneca | P4 | BBB |
| (+)-Vincristine | Janssen Research & Development, LLC | P3 | BBB |
| Aclacinomycin | Chinese PLA General Hospital | P4 | BB |
| Idarubicin | Institute of Hematology & Blood Diseases Hospital, China | P4 | BB |
| Daunomycin | Shen yang | P4 | BB |
| Amsacrine | University Hospital, Toulouse | P4 | BB |
| Etoposide | Memorial Sloan Kettering Cancer Center | P4 | BB |
+42 more in the Acute Myeloid Leukemia cohort
Other indications for Tagraxofusp-Erzs
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| CD4+/CD56+ Hematodermic Neoplasm | — | P2 | C · 36 |
| Lymphoblastic Lymphoma | — | P1/2 | C · 33 |
| B-Cell Acute Lymphoblastic Leukemia | — | P1/2 | C · 33 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tagraxofusp-Erzs in Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tagraxofusp-erzs-acute-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →